Cholinergic Status and the Metabolic Syndrome
Choliner stat
1 other identifier
interventional
50
0 countries
N/A
Brief Summary
The investigators aims in the current study are to examine whether the cholinergic status should be considered as another risk factor for the metabolic syndrome and it's co-morbidities and to test the effect of a hypocaloric high complex carbohydrates diet on the cholinergic status of overweight and obese adults with and without the metabolic syndrome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2011
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2011
CompletedFirst Submitted
Initial submission to the registry
April 7, 2011
CompletedFirst Posted
Study publicly available on registry
April 11, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2011
CompletedApril 11, 2011
April 1, 2011
4 months
April 7, 2011
April 8, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
total soluble circulation capacity for acetylcholine hydrolysis
8 weeks or more
Secondary Outcomes (3)
Inflammatory markers
8 weeks or more
ROTEM - rotation thromboelastometry
8 weeks or more
Metabolic markers
8 weeks or more
Study Arms (1)
Obese and overweight subjects
EXPERIMENTALThe participants are overweight and obese people with and without metabolic syndrome that will participate in diet groups.
Interventions
diet groups that meet every week for eight weeks or more.
Eligibility Criteria
You may qualify if:
- BMI ≥ 25kg/m2
- Stable weight (±1kg)in the previous six months
- Non smokers
You may not qualify if:
- Type II diabetes
- Hypertension pharmacologically treated
- Cardiovascular disease
- Renal disease
- Cirrhosis and end-stage liver failure
- Thyroid disease
- Cerebrovascular disease
- Cancer
- Autoimmune disease
- Chronic inflammatory disease
- Surgery or heart catheterization in the previous six months
- Use of drugs known to affect measured parameters
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
April 7, 2011
First Posted
April 11, 2011
Study Start
April 1, 2011
Primary Completion
August 1, 2011
Study Completion
September 1, 2011
Last Updated
April 11, 2011
Record last verified: 2011-04